Form 4: ZIVO Director Acquires Stock Options

Zivo Bioscience Director Alison Cornell acquired 1,223 nonstatutory stock options as part of her compensation.

Summary

• Director Alison Cornell acquired 1,223 nonstatutory stock options for Zivo Bioscience, Inc. common stock.
• The options have an exercise price of $12.03 per share.
• The options were issued on October 2, 2025, and become exercisable on the same date, expiring on October 2, 2035.
• These options were granted under the 2024 Equity Incentive Plan for Non-Employee Directors.
• The grant was in lieu of retainer fees totaling $12,476.71.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. It's a routine compensation event, not a major strategic announcement.

Positives

• Director Alison Cornell's acquisition of stock options aligns her interests with shareholders, indicating confidence in the company's future.
• The use of stock options as compensation for non-employee directors is a common practice to incentivize long-term performance and conserve cash.

Risks

• The value of the stock options is dependent on the future performance of Zivo Bioscience's common stock. If the stock price does not exceed the exercise price of $12.03, the options may expire worthless.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from the company. However, the grant of options implies a long-term view for the director's incentive.

Management Comments

• The option was issued to the reporting person pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $12,476.71.

Industry Context

Granting stock options to non-employee directors is a standard practice across many industries to align director incentives with shareholder value creation and conserve cash. This transaction reflects a routine compensation event within the bioscience sector.

Comparison to Industry Standards

• The practice of compensating non-employee directors with equity, such as stock options, is a common corporate governance standard, seen in companies like Apple Inc. (AAPL) or Microsoft Corp. (MSFT), which use restricted stock units (RSUs) or options to align director interests with long-term shareholder value.
• The specific value of the retainer ($12,476.71) and the number of options (1,223) would need to be compared against peer companies in the bioscience sector to assess if it's within typical ranges, but this filing does not provide that comparative data.

Corporate Governance

Stakeholder Impact

• Shareholders: Director's interests are further aligned with shareholders through equity ownership.
• Company: Conserves cash by compensating directors with equity instead of cash for retainer fees.

Next Steps

• Alison Cornell will hold these options until their expiration date of October 2, 2035, unless exercised earlier.
• Any future exercise or sale of the underlying common stock by Alison Cornell would require a new Form 4 filing.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where a director received stock options as part of their compensation. While it indicates alignment of interests, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Investors should hold their position and await more substantive operational or financial updates.

Keywords

Zivo Bioscience, ZIVO, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Incentive Plan